VFMCRP announces U.S. Court upholds validity of Velphoro® patent
14.9.2022 16:05:00 EEST | Business Wire | Press release
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251 which covers the formulation for Velphoro® (sucroferric oxyhydroxide). The decision, subject to appeal, holds that the generic sucroferric oxyhydroxide product proposed by Teva Pharmaceuticals USA, Inc., in its Abbreviated New Drug Application (ANDA) will infringe the Velphoro® U.S. patent no. 9,561,251, which expires in July 2030 (including pediatric extension). Currently, Velphoro® is protected by multiple Orange Book listed patents which expire between May 2029 and May 2035.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220821005007/en/
A further ANDA patent infringement lawsuit against Teva based on patents no. 10,682,376, no. 10,695,367 and no 11,013,761, all expiring in May 2029 remains pending.
“CSL Vifor welcomes the decision by the U.S. District Court to uphold the patent validity of Velphoro® which highlights the innovation and strength of our intellectual property,” said Florian Jehle, Chief Executive Officer of VFMCRP. “We are vigorously defending our intellectual property and protecting our market position. With this decision, we can continue to deliver this innovative drug to improve the lives of patients with chronic kidney disease on dialysis.”
VFMCRP has previously settled disputes with Lupin Pharmaceuticals, Inc and Annora Pharma Pvt. Ltd. which had filed ANDAs to market a generic version of Velphoro®. These ANDA filers will be able to launch a generic version of Velphoro® in the United States on an agreed-upon date. Details of all settlements are confidential.
About CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.
About Velphoro®
Velphoro® is a non-calcium, iron-based, chewable phosphate binder approved for the control of phosphate levels in the blood of adults with chronic kidney disease on dialysis. Velphoro® has been launched in 32 countries at the end of 2021, with more than 100,000 patients estimated to use the drug on a yearly basis.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220821005007/en/
Contact information
CSL Vifor Media Contact
Thomas Hutter
Mobile: +41 79 957 96 73
Email: media@viforpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Experian Brings Trusted Agentic AI to Financial Services With the Launch of Agent Operating System™2.6.2026 16:05:00 EEST | Press release
Experian today announces the launch of the Agent Operating System™, a trusted agentic AI layer within the Experian Ascend Platform, unveiled at Money20/20 Europe. The Experian Agent Operating System is designed to help financial services organisations move successfully beyond AI experimentation and safely scale agentic AI to transform decision-making, customer experiences, and day-to-day operations. It enables AI agents from Experian, clients and partners to work together through a common trust, semantic and orchestration layer, supported by clear controls, auditability and human oversight. The launch comes as financial services firms accelerate investment in AI but continue to face major barriers to scaling adoption. New Experian research* shows that nearly half of global organisations (48%), say integrating data into AI workflows remains difficult, while a third cite poor data lineage and a further third say data is siloed across teams and systems. At the same time, consumers are inc
High Q Technologies and Creative Biostructure Announce Strategic Partnership Expanding Global Access to Quantum-Enabled EPR Spectroscopy2.6.2026 16:00:00 EEST | Press release
High Q Technologies, a developer of quantum-enabled electron paramagnetic resonance (EPR) spectroscopy systems, and Creative Biostructure, a structural biology Contract Research Organization, today announced a strategic partnership to support broader adoption of EPR spectroscopy for studying protein dynamics in pharmaceutical and biotechnology research. EPR spectroscopy is increasingly relevant as drug discovery turns toward disordered, flexible, and disease‑relevant protein systems that cannot be fully understood through static structural methods alone. However, broad adoption of EPR has historically been limited by instrument and workflow complexity, and the need for dedicated technical expertise in experimental design and data interpretation. Leveraging quantum sensor technology, FATHOM® EPR has overcome these challenges. By providing unique measurements of long‑range distances, FATHOM® EPR enables researchers to probe conformational ensembles and molecular motion implicated in toda
Lenovo Technology Powers FIFA World Cup 2026™ Operations and Strengthens AI-Driven Broadcast2.6.2026 16:00:00 EEST | Press release
Lenovo today announced it is delivering a near real-time AI-powered infrastructure platform for the FIFA World Cup 2026™ to enable ultra-low-latency IPTV (Internet Protocol Television) video distribution in addition to the traditional cable and satellite broadcast, intelligent content delivery, and mission-critical decision-making across the event ecosystem and operations. As the world’s largest sporting event prepares for an unprecedented scale—spanning three host countries, featuring 48 teams, and engaging an estimated 6 billion fans—FIFA, broadcasters, and event operators will benefit from a live, always-on environment designed to perform at the highest level. As FIFA’s Official Technology Partner, Lenovo will deploy servers at the International Broadcast Center in Dallas, Texas, to help deliver the computing power, devices, and AI-driven solutions needed to bring every moment of every match to global audiences and support the most expansive broadcast operation in FIFA World Cup™ hi
New Tacton Research Reveals Only 7% of Manufacturers Have Achieved End-to-End Value Chain Connectivity2.6.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex, highly configurable products, today released its annual State of Manufacturing report, revealing that rising product complexity is exposing critical cross-functional gaps despite continued investment in digital transformation and AI. Based on a survey of 280 manufacturing leaders in eight countries, the research found that 67% now describe their products as “very” or “extremely” complex, a 20-point increase in just one year. At the same time, only 7% use the same product configuration rules across every team and system involved in selling and building products, which is critical for reducing margin risk because of siloed functions and data. The report highlights a growing industry reality: while digital transformation has modernized operations, rising complexity is exposing disconnects between systems, team, and data throughout the manufacturing lifecycle. "Digital transformation laid the f
HTEC and Xsolis’ Strategic Partnership to Tackle Inefficiencies in Healthcare Decision-Making with AI2.6.2026 15:38:00 EEST | Press release
HTEC, the global AI-first engineering and digital product development company, today announced a strategic partnership with Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602462348/en/ HTEC, the global AI-first engineering and digital product development company, today announced a strategic partnership with Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers. Across healthcare systems, determining whether a treatment is medically necessary, what level of care a patient requires, and whether that care will be approved remains a slow, manual, and often inconsistent process. Known as utilization management, this function sits at the heart of healthcare operations—but is still heavily reliant on fragm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom